Persistent URL of this record https://hdl.handle.net/1887/3276328
Documents
-
- Download
- 122377130_submittedVersion_fz5hef4vcyy9axztfxlm
- Submitted Manusript (under Review)
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743) a multicentre, randomised, open-label, phase 3 trial
- All authors
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; Oulkhouir, Y.; Bautista, Y.; Cornelissen, R.; Greillier, L.; Grossi, F.; Kowalski, D.; Rodriguez-Cid, J.; Aanur, P.; Oukessou, A.; Baudelet, C.; Zalcman, G.
- Date
- 2021-01-30
- Journal
- The Lancet
- Volume
- 397
- Issue
- 10272
- Pages
- 375 - 386